DICERNA PHARMACEUTICALS, INC. DRNA Income Statement

Dicerna pharmaceuticals, inc. (DRNA)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Revenue
54,825	23,904	18,365	11,875	7,738	6,176	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Operating expenses:
Research and development
130,907	109,339	88,294	69,903	57,410	45,700	41,489	38,321	37,050	35,900	35,380	36,914	38,878	41,399	43,619	45,700	46,543	43,971	42,616	37,963	32,894	29,453	23,743	18,684	14,391	11,558	0	0	0
General and administrative
49,098	42,751	36,362	31,097	27,026	21,685	17,588	16,371	15,677	16,838	15,654	15,855	16,445	15,433	17,897	18,416	18,279	19,240	19,531	18,399	18,252	15,648	13,178	10,755	7,525	5,820	0	0	0
Litigation expense
-	-	10	3,704	-	29,132	31,670	30,210	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
180,005	152,090	124,677	104,715	110,395	96,528	92,448	86,917	64,942	61,769	58,732	57,919	58,239	59,748	61,516	64,116	64,822	63,211	62,147	56,362	51,146	45,101	36,921	29,439	21,916	17,378	0	0	0
Loss from operations
-125,180	-128,186	-106,312	-92,840	-102,657	-90,352	-86,783	-82,797	-62,367	-60,739	-58,894	-57,919	-58,239	-59,748	-61,354	-64,116	-64,638	-63,027	-61,963	-56,178	-51,146	-45,101	-36,921	-29,439	-21,916	-17,378	0	0	0
Other income (expense):
Preferred stock warrant liability re-measurement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,559	-2,658	-2,562	-2,680	-126	0	0	0
Loss on extinguishment of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	-	-
Interest income
8,132	7,537	7,117	5,638	3,832	2,102	1,198	976	789	539	413	295	218	235	228	222	190	188	172	138	112	63	34	0	0	-	0	-	0
Interest expense
7	3	223	399	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	199	391	632	839	952	0	0	0
Other income
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income, net
8,383	7,727	6,212	4,486	0	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-2,838	-3,150	-3,633	-3,587	-1,140	0	0	0
Net loss
-116,797	-120,459	-99,399	-87,629	-99,428	-88,853	-85,984	-81,997	-61,578	-60,200	-58,481	-57,624	-58,021	-59,513	-61,126	-63,894	-64,448	-62,839	-61,791	-56,040	-51,219	-47,939	-40,071	-33,072	-25,503	-18,518	0	0	0
Foreign currency translation adjustment
-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redeemable Preferred Stock Dividends
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock Conversions, Inducements
-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: accretion and dividends on redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	204	213	559	1,581	2,388	0	0	0
Net Income (Loss) Available to Common Stockholders, Basic
-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-48,143	-40,284	-33,631	-27,084	-20,906	0	0	0
Net loss per share – basic and diluted (in dollars per share)
-0.31	-0.58	-0.45	-0.35	-0.38	-0.27	-0.35	-0.68	-0.30	-0.91	-0.92	-1.15	-0.68	-0.68	-0.68	-0.75	-0.76	-0.62	-0.82	-0.86	-0.79	-0.71	-0.63	-0.64	-1.02	-204.09	-161.55	-171.13	-172.80
Weighted average common shares outstanding – basic and diluted (in shares)
72,919	68,768	68,360	68,323	68,259	63,385	54,799	52,555	51,723	25,242	20,841	20,794	20,791	20,753	20,752	20,726	20,646	24,021	20,592	18,852	17,815	18,066	17,706	17,684	10,822	33	28	28	27